NCT02944214

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Middle-to-late Stages of Chronic Kidney Disease Patients: a Multi-center Randomized Controlled Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 800 (estimated)
• Sponsor: Shanghai 10th People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.

Detailed description

Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-60 ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid, serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.

Conditions

• Chronic Kidney Disease
• Hyperuricemia
• Abnormal Renal Function

Interventions

Type	Name	Description
DRUG	Febuxostat	It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
DRUG	Benzbromarone	It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase

Timeline

• Start date: 2016-10-01
• Primary completion: 2019-12-01
• Completion: 2019-12-01
• First posted: 2016-10-25
• Last updated: 2016-10-25

Locations

1 site across 1 country: China